Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The prevalence of diabetes is up to 11.6% according to the data released in 2013 by the China
Noncommunicable Disease Surveillance Group.Less than 40% of all diagnosed-diabetes were well
controlled.Among all kinds of antidiabetic medications, metformin is recommended as the
first-line antihyperglycemic management for type 2 diabetes. Insulin secretagogue,repaglinide
is still one of the most widely used antidiabetic medications in China. However, there were
few studies comparing the effects of these two medications on glycaemic control in Chinese
patients with type 2 diabetes.